CSI Market
Sign In | Register

Mediwound Ltd (MDWD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MDWD Annual Cash Flow →
Tracking cash flow results across Mediwound Ltd to Dec 31 2024 helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-23.71
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss0.05
Financial Instruments and Foreign Currency Transaction0.00
Profit Loss From Discontinued Operations-
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Sharebased Payments-
Revaluation Of Liabilities In Respect Of Grants-
Adjustments For Increase Decrease In Other Income-
Adjustments For Increase Decrease In Employee Benefit Liabilities-
Adjustments For Reconcile Profit Loss-
Adjustments For Increase Decrease In Trade Account Payable-
Adjustments For Increase Decrease In Other Payables And Deferred Revenue-
Adjustments For Changes In Increase Decrease In Asset And Liability Items-
Cash Flows From Used In Operating Activities Continuing Operations-
Cash Flows From Used In Operating Activities Discontinued Operations-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable3.21
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Other Adjustments To Reconcile Profit Loss0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-9.41
Discontinued operations0.00
Net Cash flow from Operating Activities-16.12
Investing Activities
Capital Expenditures5.51
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Interest Received Classified As Investing Activities-
Cash Flows From Used In Decrease Increase In Shortterm Deposits And Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans1.21
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-17.95
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net3.63
Other net6.77
Proceeds From Issuing Shares-
Increase Decrease In Cash And Cash Equivalents-
Increase Decrease In Cash And Cash Equivalents Discontinued Operations-
Proceeds From Exercise Of Warrants-
Proceeds From Issuance Of Shares And Warrants Net-
Repayments Of Iia Grants Net-
Repayment Of Liabilities In Respect Of Teva-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities29.62
Effect of exchange rate on cash flow0.10
Discontinued operations0.00
Free Cash Flow-10.62
Total Cash Flow9.16
4 historic quarters locked

Sign in to unlock the full Mediwound Ltd cash flow history.

Sign In Create Free Account

About Mediwound Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 5, 2026
  • Source: zk2634458.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178913-26-000749

Figures are derived from filed reports and may be restated. Historical data is subject to revision.